Patent ID: 11967399
Assignee: SHENZHEN NEOCURA BIOTECHNOLOGY CORPORATION
Field: Biotechnology (Chemistry)
Classification: CPC C  G | IPC C  G

Claim 0:
1. A method for calculating tumor neoantigen burden (TNB) and treating a tumor, comprising:
step S0: obtaining a normal tissue sample and a tumor tissue sample from a patient;
step S1: processing the normal tissue sample and the tumor tissue sample from the patient by sequencing a specific region and detecting somatic mutations in the patient;
step S2: annotating and filtering the somatic mutations to obtain filtered somatic mutations, and translating the filtered somatic mutations to obtain mutant peptide sequences of the patient;
step S3: filtering the mutant peptide sequences to obtain neopeptide sequences based on a proteome of the normal sample;
step S4, performing a human leukocyte antigen (HLA) typing analysis based on alignment data of the normal sample to obtain HLA genotypes of the patient;
step S5: predicting binding affinities between the neopeptide sequences and the HLA genotypes to obtain specific neoantigens of the patient, and performing a weighted scoring on each of the specific neoantigens and calculating the TNB of the patient, wherein the performing the weighted scoring on the patient comprises:
step S501: predicting the binding affinities between the neopeptide sequences and the HLA genotypes to obtain the specific neoantigens of the patient;
step S502: calculating a weight value of each of the specific neoantigens by combining mutation annotation information, mutation frequency information and binding affinities to HLA genotype information, wherein different scores are marked for neoantigen mutation frequency and neoantigens from different mutation frequency ranges, different scores are marked for neoantigens with different mutation filtering information, and different scores are marked for rank results of the neoantigen binding affinity prediction, then the weight value of each of the neoantigens is obtained by comprehensively calculating each of the different scores for each respective neoantigen,
step S503: accumulating the weight value of each of the specific neoantigens by comprehensively calculating weight values of all of the neoantigens based on to obtain the TNB of the sample, and

predicting a therapeutic effect of an immune checkpoint inhibitor on the tumor based on the weight value of each of the specific neoantigens, and administering an effective immune checkpoint inhibitor to treat the tumor in the patient based on the predicted therapeutic effect and calculated TNB of the sample.